Some insights into backend work with ATL-1102

For those that would like to get a greater understanding of many R&D backend processes and trials and tribulations.
The effect and relationship between ATL-1102 and CD49d and the hurdles that arise and potential pathways to overcome some of these hurdles.
There is clearly a lot of work with testing , results and hypothesis and conjecture to move things forward.
An example is that a product may not achieve efficacy not because it doesnt work, but possibly the mechanism of delivery is restricting it.
There is a lot of insight in this article, if you are curious or bored
I found it another very interesting article when you break it up and look at the different componants and also from different angles and or perspectives.


Effects of CD49d-targeted antisense-oligonucleotide on α4 integrin expression and function of acute lymphoblastic leukemia cells: Results of in vitro and in vivo studies - PMC (nih.gov)

ps it may take some focus to conceptualise the story.